Welcome to our dedicated page for Endo news (Ticker: NDOI), a resource for investors and traders seeking the latest updates and insights on Endo stock.
Endo, Inc. (OTCQX: NDOI) delivers specialty pharmaceutical solutions through branded therapies, generics, and sterile injectables. This news hub provides investors and industry professionals with timely updates on material developments shaping the company’s trajectory.
Track Endo’s latest press releases including earnings reports, regulatory milestones, clinical trial progress, and strategic initiatives. Our curated feed covers FDA decisions, manufacturing expansions like the Indore facility, and advancements in treatments for musculoskeletal conditions such as Dupuytren's contracture.
Key updates include financial disclosures, product pipeline developments, and operational efficiency measures. Stay informed about Endo’s clinical research presentations, supply chain optimizations, and compliance achievements that demonstrate its commitment to quality therapeutics.
Bookmark this page for centralized access to verified NDOI news. Check regularly for insights into how Endo’s diversified portfolio and patient-centric approach position it within the evolving pharmaceutical landscape.
Endo (NDOI) reported its Q4 and full-year 2024 financial results, with Q4 revenues of $467 million, down 6% from $498 million in Q4 2023. The company posted a Q4 2024 net loss of $349 million, compared to a $2,441 million loss in Q4 2023.
Key highlights include XIAFLEX® achieving record revenues of $516 million in 2024, up 9% versus 2023. The company launched three sterile injectable products, including ADRENALIN® ready-to-use premixed bags. Segment performance showed Branded Pharmaceuticals at $247 million, Sterile Injectables at $92 million, and Generic Pharmaceuticals at $111 million.
Endo provided 2025 guidance with expected revenues of $1,775 to $1,860 million and adjusted EBITDA of $620 to $650 million. The company also announced a definitive agreement to combine with Mallinckrodt plc in a cash and stock transaction.
Mallinckrodt and Endo have announced a strategic merger to create a global pharmaceuticals leader through a stock and cash transaction. The deal, expected to close in H2 2025, will see Endo shareholders receive $80 million in cash and own 49.9% of the combined entity, while Mallinckrodt shareholders will own 50.1%.
The combined company, to be listed on the NYSE, projects $3.6 billion in 2025 revenue and $1.2 billion in Adjusted EBITDA. The merger aims to generate at least $150 million in annual operating synergies by Year 3 and approximately $75 million in Year 1.
Key aspects include a net leverage of 2.3x at close, 17 manufacturing facilities, 30 distribution centers, and approximately 5,700 employees. The companies plan to combine and later separate their generics and sterile injectables businesses. Siggi Olafsson will serve as CEO of the combined entity, with Paul Efron as Board Chair.
Endo (OTCQX: NDOI) has announced the presentation of a post hoc data analysis from a Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or CCH) for Peyronie's disease at the 89th annual SESAUA meeting, March 12-15, 2025.
The analysis, presented by Dr. Gregory A. Broderick, suggests that CCH could be a viable alternative to watchful waiting for Peyronie's disease patients, regardless of their disease phase or pain status. The research specifically examines the potential benefits of CCH treatment in patients with penile pain at baseline.
The Endo-supported study involves multiple researchers, including specialists from various medical institutions, focusing on expanding treatment options for Peyronie's disease patients beyond current literature recommendations.
Endo (OTCQX: NDOI) has announced the divestiture of its International Pharmaceuticals business, primarily operated through Paladin Pharma Inc., to Knight Therapeutics Inc. for up to $99 million. The deal structure includes an $84 million upfront cash payment and potential additional $15 million in milestone-based payments.
Knight Therapeutics, specializing in innovative prescription pharmaceuticals in Canada and Latin America, will acquire Paladin Pharma, Endo's Canada-based specialty pharmaceutical subsidiary. The transaction, subject to regulatory approvals including Canadian anti-trust clearance, is expected to close in mid-2025.
Endo (OTCQX: NDOI) has announced the rescheduling of its fourth quarter and full year 2024 financial results release to March 13, 2025, before market open. The company will host a conference call at 8:00 a.m. ET on the same day.
Investors can access the audio webcast through the Investor Relations section of Endo's website at investor.endo.com under Events & Presentations. Conference call participants can dial 800-836-8184 (U.S. and Canada toll-free) or 646-357-8785 (international). Participants should join 10 minutes before the scheduled start time. A webcast replay will be available after the event.
Endo (OTCQX: NDOI) has announced a significant presentation at the joint meeting of the International Society for the Study of Women's Sexual Health (ISSWSH) and International Society for Sexual Medicine (ISSM), scheduled for February 27-March 2, 2025.
The presentation focuses on a healthcare provider survey regarding Peyronie's disease and its psychological impact on female partners. Led by urologist Dr. Irwin Goldstein, the study aims to evaluate healthcare providers' awareness and practices in addressing this condition.
The Endo-sponsored research titled 'Development of a Survey to Assess Women's Sexual Health Providers' Awareness and Approach Toward Peyronie's Disease and the Impact on the Female Sexual Partner' involves collaboration among multiple medical professionals and researchers in the field of sexual health.
Endo (OTCQX: NDOI) has announced it will release its fourth quarter and full year 2024 financial results on March 11, 2025, before the market opens. The company will host a conference call at 8:00 a.m. ET on the same day.
Investors can access the audio webcast through the Investor Relations section of Endo's website at investor.endo.com under Events & Presentations. Conference call participants can dial 800-836-8184 (U.S. and Canada toll-free) or 646-357-8785 (international). Participants should join 10 minutes before the scheduled start time. A webcast replay will be available after the event.
Endo (OTCQX: NDOI) has launched 'Steve's Journey,' its first branded TV commercial for XIAFLEX®, the only FDA-approved nonsurgical treatment for Dupuytren's contracture. The campaign features a real patient, Steve, and his wife Gisele, sharing their experience with the progressive hand condition that affects an estimated 17 million Americans.
The commercial showcases Steve's treatment journey with XIAFLEX® and demonstrates how the treatment helped him regain hand functionality for everyday activities. The 60-second spot will air across various platforms, including news, sports programming, popular TV series, cable channels, and streaming services.
The campaign builds on Endo's research showing that many patients delay treatment due to concerns about surgery. According to company data, patients who ask for XIAFLEX® by name receive the medication more than half of the time.
Endo (OTCQX: NDOI) has launched 'I Got Somebody,' a new television commercial and disease awareness campaign focused on Peyronie's disease (PD). The campaign directs men to GoGetSomebody.com to find urology specialists who can diagnose and offer treatment plans, including nonsurgical options.
PD, which affects an estimated 1 in 10 men in the U.S., is a condition where scar tissue causes a curve with a bump in the penis when erect. The campaign addresses research showing men often delay seeking treatment due to embarrassment and fear.
The commercial will run nationally on major networks like ESPN, ABC, NBC, and Fox Sports 1, streaming services including Hulu, Amazon, and Peacock, and through social media channels. The campaign showcases how men readily share recommendations for various problems and encourages them to do the same with PD-related healthcare concerns.
Endo (OTCQX: NDOI) announced the publication of their Peyronie's disease (PD) self-assessment screening app in the peer-reviewed journal Translational Andrology and Urology. The app aims to help men document curvature deformities and prepare for urologist visits, addressing the reluctance many face in discussing this intimate condition. The application features include image scans, a self-assessment questionnaire, and a provider locator. The article was authored by healthcare professionals including Gregory A. Broderick, MD, Jesse N. Mills, MD, Lisa Bathish, BA, PMP, Christopher Davis, PMP, and Mohit Khera, MD, MBA, MPH.
FAQ
What is the current stock price of Endo (NDOI)?
What is the market cap of Endo (NDOI)?
